You searched for "treatment"

810 results found

Comparing intravesical chemohyperthermia with Mitomycin C versus BCG in treating bladder cancer

In the advent of the recent Bacillus Calmette–Guérin (BCG) crisis, the importance of alternative adjuvant treatments for intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) has been highlighted. Chemohyperthermia (CHT) has emerged as an option, however there remains a lack of...

Fertility preservation for paediatric patients

Paediatric patients are at risk for future infertility due to medical conditions and treatments. As the most well-known example, many patients undergoing oncological therapy are at risk of future infertility. In addition, those receiving immunosuppressive or stem cell transplant therapy...

Prevention of urethral stricture recurrence

Urethral stricture recurrence after urethral reconstruction is one of the most challenging problems in urology. With the increase in endoscopic surgery over the last three decades the incidence of urethral strictures has increased, with iatrogenic manipulation the leading aetiology in...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Urinary tract stones

Case 1 What does this plain X-ray of kidneys, ureters and bladder (KUB) show? What, according to the 2009 The National Institute for Health and Care Excellence (NICE) guidelines, is the most appropriate first-line treatment? What factors do the NICE...

NICE backs laser for BPH

Benign prostatic hyperplasia affects 60% of men aged 60 or over. The medical technology division of the National Institute for Health & Care Excellence (NICE) has supported the GreenLight XPS laser system as a surgical tool. The specific indications are:...

Bladder Pain Syndrome – An Evolution, 2nd Edition

Bladder pain syndrome remains the focus of much debate and discussion, and this will continue in the future. This book is the second edition of Interstitial Cystitis which was published three decades ago. Given that a lot has happened in...

Movember launches world’s largest cancer real world evidence network

Movember has launched the world’s largest prostate cancer and testicular clinical and research network, aimed at improving the overall survival and quality of life for those living with diseases that affect over 1.4 million men worldwide every year. The leading...

The Underactive Bladder

For many, a diagnosis of an underactive or atonic bladder represents the end of the line in terms of management options. It remains a poorly understood and even more poorly appreciated condition, both in terms of underlying pathophysiology and alternatives...

An Insider’s Perspective of Prostate Cancer – Understanding Effects, Management Options and Consequences

This deceptively small paperback punches way above its weight compared to some of the existing hefty tomes on prostate cancer. It is an admirable effort at delivering content pitched at both the lay reader as well as the medical graduate....

Focal therapies in prostate cancer

The standard of care in the management of prostate cancer has, to date, always been to treat the whole gland. This has ranged from surveillance, surgical excision / prostatectomy or external beam radiotherapy / whole gland brachytherapy. With the evolution...

Ambulatory local anaesthetic implantation of percutaneous sacral nerve stimulators

Background The current treatment paradigm for detrusor overactivity (DO) and dysfunctional voiding (DV) includes conservative measures, pharmacotherapy, intravesical onabotulinum toxin A (Botox®), sacral nerve modulation (SNM / SNS) and urinary diversion as a last resort [1]. Incidence of DO is...